A novel cell-free screen identifies a potent inhibitor of the fanconi anemia pathway

Igor Lanclais, Alexandra Sobeck, Stacie Stone, Alexis LaChapelle, Maureen Hoatlin

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The Fanconi Anemia (FA) DNA damage response pathway is involved in the processing of DNA interstrand crosslinks (ICLs). As such, inhibition of the FA pathway could chemosensitize FA-competent tumor cells to commonly used ICL agents like cisplatin. Moreover, suppression of the FA pathway is synthetic lethal with deiciencies in several other DNA repair pathways, suggesting that FA pathway inhibitors could be used in targeted therapies against speciic tumors. To identify such inhibitors, we designed a novel in vitro screening assay utilizing Xenopus egg extracts. Using the DNA-stimulated monoubiquitylation of Xenopus FANCD2 (xFANCD2-L) as readout, a chemical library screen identiled DDN (2,3-dichloro-5,8-dihvdroxv-l,4-naphthoquinone) as a novel and potent FA pathway inhibitor. DDN inhibited xFANCD2-L formation in a dose-dependent manner in both extracts and human cells without disruption of the upstream FA core complex. DDN also inhibited the characteristic subnuclear FANCD2 foci formation following DNA damage. Moreover, DDN displayed a greater synergistic effect with cisplatin in a FA-proicient cancer cell line compared to its FA-deicient isogenic counterpart, suggesting that DDN might be a good lead candidate as cisplatin che-mosensitizer in both FA-deicient and FA-competent tumors. This system constitutes the first cell-free screening assay for identifying compounds that inhibit the FA pathway and provides a new biochemical platform for mapping the functions of its various components with specific chemical inhibitors.

Original languageEnglish (US)
Pages (from-to)783-792
Number of pages10
JournalInternational Journal of Cancer
Volume124
Issue number4
DOIs
StatePublished - Feb 15 2009

Fingerprint

Fanconi Anemia
Naphthoquinones
Cisplatin
Xenopus
DNA Damage
Neoplasms
Small Molecule Libraries
DNA
Cell Extracts
DNA Repair
Ovum

Keywords

  • Chemosensitization
  • Cisplatin
  • DNA repair
  • Interstrand crosslinks

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

A novel cell-free screen identifies a potent inhibitor of the fanconi anemia pathway. / Lanclais, Igor; Sobeck, Alexandra; Stone, Stacie; LaChapelle, Alexis; Hoatlin, Maureen.

In: International Journal of Cancer, Vol. 124, No. 4, 15.02.2009, p. 783-792.

Research output: Contribution to journalArticle

Lanclais, Igor ; Sobeck, Alexandra ; Stone, Stacie ; LaChapelle, Alexis ; Hoatlin, Maureen. / A novel cell-free screen identifies a potent inhibitor of the fanconi anemia pathway. In: International Journal of Cancer. 2009 ; Vol. 124, No. 4. pp. 783-792.
@article{1c6d1f60d1584b3fa02f2061f3fbb43b,
title = "A novel cell-free screen identifies a potent inhibitor of the fanconi anemia pathway",
abstract = "The Fanconi Anemia (FA) DNA damage response pathway is involved in the processing of DNA interstrand crosslinks (ICLs). As such, inhibition of the FA pathway could chemosensitize FA-competent tumor cells to commonly used ICL agents like cisplatin. Moreover, suppression of the FA pathway is synthetic lethal with deiciencies in several other DNA repair pathways, suggesting that FA pathway inhibitors could be used in targeted therapies against speciic tumors. To identify such inhibitors, we designed a novel in vitro screening assay utilizing Xenopus egg extracts. Using the DNA-stimulated monoubiquitylation of Xenopus FANCD2 (xFANCD2-L) as readout, a chemical library screen identiled DDN (2,3-dichloro-5,8-dihvdroxv-l,4-naphthoquinone) as a novel and potent FA pathway inhibitor. DDN inhibited xFANCD2-L formation in a dose-dependent manner in both extracts and human cells without disruption of the upstream FA core complex. DDN also inhibited the characteristic subnuclear FANCD2 foci formation following DNA damage. Moreover, DDN displayed a greater synergistic effect with cisplatin in a FA-proicient cancer cell line compared to its FA-deicient isogenic counterpart, suggesting that DDN might be a good lead candidate as cisplatin che-mosensitizer in both FA-deicient and FA-competent tumors. This system constitutes the first cell-free screening assay for identifying compounds that inhibit the FA pathway and provides a new biochemical platform for mapping the functions of its various components with specific chemical inhibitors.",
keywords = "Chemosensitization, Cisplatin, DNA repair, Interstrand crosslinks",
author = "Igor Lanclais and Alexandra Sobeck and Stacie Stone and Alexis LaChapelle and Maureen Hoatlin",
year = "2009",
month = "2",
day = "15",
doi = "10.1002/ijc.24039",
language = "English (US)",
volume = "124",
pages = "783--792",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - A novel cell-free screen identifies a potent inhibitor of the fanconi anemia pathway

AU - Lanclais, Igor

AU - Sobeck, Alexandra

AU - Stone, Stacie

AU - LaChapelle, Alexis

AU - Hoatlin, Maureen

PY - 2009/2/15

Y1 - 2009/2/15

N2 - The Fanconi Anemia (FA) DNA damage response pathway is involved in the processing of DNA interstrand crosslinks (ICLs). As such, inhibition of the FA pathway could chemosensitize FA-competent tumor cells to commonly used ICL agents like cisplatin. Moreover, suppression of the FA pathway is synthetic lethal with deiciencies in several other DNA repair pathways, suggesting that FA pathway inhibitors could be used in targeted therapies against speciic tumors. To identify such inhibitors, we designed a novel in vitro screening assay utilizing Xenopus egg extracts. Using the DNA-stimulated monoubiquitylation of Xenopus FANCD2 (xFANCD2-L) as readout, a chemical library screen identiled DDN (2,3-dichloro-5,8-dihvdroxv-l,4-naphthoquinone) as a novel and potent FA pathway inhibitor. DDN inhibited xFANCD2-L formation in a dose-dependent manner in both extracts and human cells without disruption of the upstream FA core complex. DDN also inhibited the characteristic subnuclear FANCD2 foci formation following DNA damage. Moreover, DDN displayed a greater synergistic effect with cisplatin in a FA-proicient cancer cell line compared to its FA-deicient isogenic counterpart, suggesting that DDN might be a good lead candidate as cisplatin che-mosensitizer in both FA-deicient and FA-competent tumors. This system constitutes the first cell-free screening assay for identifying compounds that inhibit the FA pathway and provides a new biochemical platform for mapping the functions of its various components with specific chemical inhibitors.

AB - The Fanconi Anemia (FA) DNA damage response pathway is involved in the processing of DNA interstrand crosslinks (ICLs). As such, inhibition of the FA pathway could chemosensitize FA-competent tumor cells to commonly used ICL agents like cisplatin. Moreover, suppression of the FA pathway is synthetic lethal with deiciencies in several other DNA repair pathways, suggesting that FA pathway inhibitors could be used in targeted therapies against speciic tumors. To identify such inhibitors, we designed a novel in vitro screening assay utilizing Xenopus egg extracts. Using the DNA-stimulated monoubiquitylation of Xenopus FANCD2 (xFANCD2-L) as readout, a chemical library screen identiled DDN (2,3-dichloro-5,8-dihvdroxv-l,4-naphthoquinone) as a novel and potent FA pathway inhibitor. DDN inhibited xFANCD2-L formation in a dose-dependent manner in both extracts and human cells without disruption of the upstream FA core complex. DDN also inhibited the characteristic subnuclear FANCD2 foci formation following DNA damage. Moreover, DDN displayed a greater synergistic effect with cisplatin in a FA-proicient cancer cell line compared to its FA-deicient isogenic counterpart, suggesting that DDN might be a good lead candidate as cisplatin che-mosensitizer in both FA-deicient and FA-competent tumors. This system constitutes the first cell-free screening assay for identifying compounds that inhibit the FA pathway and provides a new biochemical platform for mapping the functions of its various components with specific chemical inhibitors.

KW - Chemosensitization

KW - Cisplatin

KW - DNA repair

KW - Interstrand crosslinks

UR - http://www.scopus.com/inward/record.url?scp=58149457080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149457080&partnerID=8YFLogxK

U2 - 10.1002/ijc.24039

DO - 10.1002/ijc.24039

M3 - Article

VL - 124

SP - 783

EP - 792

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -